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Abstract
The use of synthetic peptides as immunogens represents an exciting alternative to traditional vaccines. However,
to date most of these synthetic peptides are not highly immunogenic. The lack of immunogenicity might be
addressed by conjugation between T or B cell epitopes with universal or immunodominant T-helper epitopes. The
construction of lipidated peptides, branched peptides, or designs combining both of these elements might
enhance the immunogenicity, as they might target Toll-Like Receptors and/or mimic the 3-dimensional structure of
epitopes within the native protein. Herein, a recognized peptide immunogen based on the hemagglutinin protein
of A/Puerto Rico/8/34 was chosen as a backbone and modified to evaluate if the construction of branched
peptides, lipidation, the addition of cysteine residues, or mutations could indeed alter epitope reactivity. Screening
the different designs with various antibody binding and cellular assays revealed that combining a branched design
with the addition of lipid moieties greatly enhanced the immunoreactivity.
Background
Influenza virus is a leading cause of disease worldwide,
affecting up to 500 million people each year. Most com-
monly spread by aerosols, symptoms of viral infection
are varied and can include headaches, sneezing, fever,
and general discomfort. Although most people are able
to clear the virus without any major complications,
infections can progress to pneumonia in children, the
elderly and otherwise immunocompromised patients,
causing an estimated 500,000 deaths per season. These
statistics change drastically during pandemics, as was
seen during the recent H1N1 outbreak wherein a single
strain of influenza caused an estimated 18 500 deaths
[1]. There are vaccines available to prevent influenza
infection, and it is recommended that all patients above
the age of 6 months receive a yearly vaccination [2].
However, the vaccines currently on the market suffer
from several weaknesses. The viral surface glycoproteins
(hemagglutinin and neuraminidase) regularly undergo
amino acid changes that often lead to new variant
strains [3]. As a result, the seasonal influenza vaccine
must be reformulated and readministered on a yearly
basis. Production of vaccine is in itself a laborious and
costly process; each strain included in the formulation
needs to be harvested from the allantoic fluid of
embryonated chicken eggs, purified and inactivated. Pro-
duction can take up to 9 months, and vaccines need to
be stored at temperatures below 8 degrees Celsius, and
cannot be given to individuals with egg allergies [4].
An interesting alternative to “traditional” vaccines
would be the use of synthetic viral peptides as immuno-
gens. In terms of manufacturing, these compounds can
be rapidly and relatively affordably mass-produced.
Additionally, the need for refrigeration is eliminated as
peptides can be stably kept as dry powder for long peri-
ods of time. From an immunological point of view, vac-
cination with short and well-defined peptides may be
preferential to immunizing with whole viral proteins.
Since the ability to induce humoral and cellular immune
responses is limited to specific regions (epitopes) within
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immulogically important epitopes could result in more
focused and thus stronger cellular and humoral
responses [3,5]. On the other hand, peptide immuno-
gens may suffer from inherent weaknesses. Proteases
may degrade the peptides before they reach their
intended targets, and there is also the risk of formation
of dimers and other types of aggregates (via reactive
terminal cysteine residues) [6]. Of greatest significance
is the fact that short peptides elicit only moderate
immune responses at best [5].
However, there are several approaches that might
increase the stability and immunogenicity of peptide
immunogens. Coupling peptides to lipid moieties has
been found to increase the biological half-life of syn-
thetic peptides [7]. The addition of lipid moieties has
also been shown to have an adjuvant-like effect, enhan-
cing otherwise moderate immune responses; lipidated
influenza peptides were found to enhance specific CD8
+
immune responses [8]. Furthermore, addition of lipid
chains to peptides resulted in more efficient cytosolic
uptake and prolonged presentation events [9], and lipi-
dated peptides were found to be better immunogens
than non-lipidated equivalents in terms of inducing
HCV-specific humoral immune responses in HCV-naïve
blood donors [10,11]. As opposed to chemical adjuvants
such as alum, lipid moieties have been tested in human
trials with few or no side effects [12]. Although the pre-
cise mechanisms whereby lipid side chains achieve their
adjuvanticity have to date not been elucidated, various
studies suggest that Toll-like receptor 2 (TLR-2) is
involved in binding lipidated peptides [13,14]. Of parti-
cular importance to a potential influenza vaccine candi-
date, this receptor is expressed on the epithelia of air
passages. The lipid-TLR-2 interaction has been found to
lead to activation of dendritic cells as evidenced by the
up-regulation of MHC class II molecules and to induce
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-B)[6,15], as well as trigger inflammatory sig-
nalling pathways in macrophages resulting in the pro-
duction of tumor necrosis factor-alpha (TNF-a),
interleukin-6 (IL-6), and monocyte chemotactic protein-
1 (MCP-1) [16].
Linking several epitopes in a dendrimer-like arrange-
ment may represent another method of enhancing the
stability of peptide immunogens; that is, constructing
poly-peptide structures or Multiple Antigen Peptides
(MAPs). Increased molecular size has been correlated to
decreased degradation and thus a longer serum half-life
[17]. Both computer modeling and electrophoretic ana-
lysis also suggest that linking the influenza T-helper and
B-cell epitopes used herein orients the peptides in a
more compact and globular shape than when these are
not linked [7]. Moreover, linked epitopes in a branched
MAP construct should attain a more natural conforma-
tion, which may in turn lead to enhanced recognition
and increased binding with B-cells. Therefore, this strat-
egy is another technique to make potential epitope-
based vaccines more immunogenic; joining T-helper
epitopes to B-cell epitopes leads to stronger immune
responses, possibly as mediated by T-B-cell cooperation
[5,7]. Indeed, previous results suggest that the manner
in which peptides are oriented have an important effect
on their immunogenicity; enhanced reactivity is achieved
when epitopes are arranged such that native antigenic
conformation is mimicked [18,19]. Furthermore, having
multiple antigens per molecule means that more epi-
topes are available to interact with antigen presenting
cells (APCs), and may thus activate stronger immune
responses [20].
Brumeanu’s group immunized mice with a short syn-
thetic influenza peptide consisting of a T-helper epitope
linked to a synthetic and immunodominant influenza B-
cell epitope, based on the H1N1 strain A/Puerto Rico/8/
34. Although only modest humoral and cellular immune
responses were detected in vaccinated animals, no sig-
nificant responses were detected in the group that had
been administered equimolar amounts of non-linked T
and B peptides [7]. With this in mind, we attempted to
modify the simple linked T-B peptide design such as to
build a more effective immunogen. In the present study,
we compare the effect that lipidation, the construction
of MAPs, the addition of a cysteine residue, and certain
mutations have on immunoreactivity. Using a bioinfor-
matic approach, we designed and synthesized an array
of 16 unique peptides, representing the two previously
studied antigenic sites from the hemagglutinin protein
of the influenza strain A/Puerto Rico/8/34. Various in
vitro assays were used to screen individual constructs
for differences in reactivity in both humoral and cellular
assays, for future use in animal studies. Commercial
strain-specific anti-influenza sera, and immune human
plasma and peripheral blood mononuclear cells
(PBMCs) were used to characterize differences in the
reactivity of peptides. Our in vitro humoral and cellular
results suggest that the most critical factor to be consid-
ered in terms of improving immunoreactivity is mimick-
ing a more native epitope conformation. This can be
easily achieved while still maintaining a relatively simple
design by constructing branched and lipidated peptides.
Materials and methods
Peptide synthesis and purification
Peptides based on the influenza A/Puerto Rico/8/34
H1N1 strain hemagglutinin (HA) were synthesized by
the solid phase method on a Symphony Peptide Synthe-
sizer (Protein Technologies, Tucson AZ). Briefly, amino
acids were coupled in sequential format from the
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ycarbonyl (FMOC) chemistry. Peptide stock solutions
were then prepared by dissolving lyophilized prepara-
tions in double distilled water at a concentration of 5
mg/ml and stored at -80°C until use.
Altogether 16 peptides were constructed; a simple
construct consisting of a T-helper epitope (
110HA
120,
sequence SFERFEIFPKE) linked by two glycine spacers
(GG) to a B-cell epitope (
150HA
159, sequence WLTE-
KEGSYP), and 15 modifications thereof. Peptides that
were lipidated had palmitic acid (CH3(CH2)14COOH)
added at the N-terminus; multiple antigen peptides
(MAPs) were constructed by creating branching points
with lysine residues; mutated peptides were designed by
aligning all post-1934 H1N1 sequences available from
the Los Alamos National Laboratory Influenza Sequence
Database (LANL ISD) [21], and comparing them using a
proprietary alignment program. Protein analysis was
done using the National Center for Biotechnology Infor-
mation Basic Local Alignment Search Tool (NCBI
BLAST) [22].
A non-influenza peptide (a T-cell epitope from the
HIV gag protein, with sequence HKGRPGNFLQNRPEP-
TAP) was obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program
(Rockville, Maryland) and was included in all assays at
the same concentration as the influenza peptides as a
negative control. Likewise, recombinant influenza
hemagglutinin protein from the A/New Caledonia/20/99
strain (Protein Sciences, Meriden, Connecticut) was
included in each assay as a positive control.
Human samples
Approximately 100 ml of peripheral blood was obtained
via venipuncture from 16 healthy donors, in accordance
with the guidelines set forth by the Children’sH o s p i t a l
of Eastern Ontario (CHEO, Ottawa, Ontario). Consent
forms were read and signed by each volunteer. For con-
fidentiality purposes, donors were assigned a number
between 1144 and 1161 (numbers 1152 and 1153 were
assigned, but donors failed to show for the blood draw
hence these numbers were skipped). The group of
volunteers consisted of 8 females and 8 males ranging
in age from 23 to 55 years old, who had been immu-
nized with the 2007/2008 FluViral influenza vaccine
(GlaxoSmithKline, London, UK). Blood was collected in
8 ml Cell Preparation Tubes (CPTs) with sodium citrate
as an anticoagulant (BD, Franklin Lakes, New Jersey).
The CPTs were allowed to sit at room temperature for
30 minutes and were gently mixed by inversion prior to
density gradient centrifugation at 1,700 Relative Centri-
fugal Force (RCF) for 25 minutes without brake. The
top layer of plasma was removed from the CPTs by
pipetting and placed at -80°C. The lower layer of
peripheral blood mononuclear cells (PBMCs) was then
isolated by washing twice with 10 ml Phosphate Buf-
fered Saline (PBS) (Thermo Fisher Scientific, Waltham,
Massachusetts). PBMCs were counted in Türk stain
(0.01% gentian violet, 1.0% acetic acid) and aliquoted in
freezing media consisting of 90% heat-inactivated fetal
b o v i n es e r u m( F B S )a n d1 0 %d i m e t h y ls u l f o x i d e
(DMSO) (Sigma-Aldrich, St. Louis, Missouri) at cell
concentrations ranging between 3 × 10
6 to 10 × 10
6
PBMCs/ml prior to storing at -80°C.
Viruses & cells
Influenza A/New Caledonia/20/99 (H1N1) and A/Puerto
Rico/8/34 (H1N1) viruses were acquired from CHEO
and the American Type Culture Collection (ATTC,
Manassas, Virginia), respectively. Viruses were propa-
gated via inoculation into the allantoic cavity of 10-day-
old embryonated chicken eggs (Canadian Food Inspec-
tion Agency, Ottawa, Canada). Virus stocks were stored
at -80°C until use.
Madin-Darby Canine Kidney (MDCK) cells (ATTC,
Manassas, Virginia) were grown in Iscove’s Modified
Dulbecco’s Medium (IMDM) (Thermo Fisher Scientific,
Waltham, Massachusetts) supplemented with 10% (v/v)
FBS and 1% penicillin/streptomycin (Cellgro, Manassas,
Virginia) in a humidified 5% CO2 atmosphere at 37°C.
ELISA
Screening by ELISA was performed as previously
described [23,24]. Briefly, EIA/RIA Stripwell 96-well
plates (Corning Incorporated, Corning, New York)
were coated with 100 μl per well of recombinant A/
New Caledonia/20/99 hemagglutinin protein (Protein
Sciences, Meriden, Connecticut) diluted to 1 μg/ml in
PBS or individual influenza or HIV gag diluted to 10
μg/ml in PBS, sealed with adhesive film and incubated
overnight at 4°C.
Plates were washed 6 times with 300 μl/well of PBS/
0.05% Tween20 (Sigma-Aldrich, St. Louis, Missouri) and
incubated for 1 hour at 37°C after the addition of 300 μl
per well of blocking buffer (either PBS/5% FBS for plates
used for influenza strain-specific sheep sera, or PBS/10%
FBS/2% skim milk for plates used for human plasma).
The plates were washed as above and incubated 1.5
hours at 37°C after the addition of 100 μlp e rw e l lo f
influenza strain-specific antiserum (sheep serum positive
for neutralizing antibodies against A/New Caledonia/20/
99, obtained from the National Institute for Biological
Standards and Controls, Herts, UK) diluted to 1/100 in
PBS/5% FBS, or heat-inactivated human plasma diluted
to 1/100 in PBS/10% FBS/2% skim milk. After this incu-
bation, the plates were washed again as previously and
incubated 1 hour at 37°C with 100 μlp e rw e l lo f1 /
10,000 rabbit anti-sheep IgG HRP-conjugate (Abcam,
Samayoa et al. Virology Journal 2011, 8:309
http://www.virologyj.com/content/8/1/309
Page 3 of 20Cambridge, Massachusetts) or 1/5000 goat anti-human
IgG HRP-conjugate (Abcam, Cambridge, Massachu-
setts). Plates were washed again and incubated at room
temperature with 100 μl per well TMB One Component
HRP Microwell Substrate (SurModics, Eden Prairie,
Minnesota). The colorimetric reaction was stopped after
8 minutes by adding 100 μl per well of 450 nm Stop
Reagent for TMB Microwell Substrates (SurModics,
Eden Prairie, Minnesota). The optical density of each
well was then read at 450 nm on a 3550-UV microplate
reader (Bio-Rad Laboratories, Hercules, California).
Competitive microneutralization assay
The competitive microneutralization assay was a modi-
fied version of a protocol previously described by our
group [25]. Briefly, heat-inactivated human plasma sam-
ples were diluted to a concentration of 1/80 in 2% FBS/
IMDM. 50 μlo fp l a s m aw e r ec o m b i n e dw i t h5 0μlo f
individual influenza or HIV gag peptide at 50 μg/ml or
50 μl of recombinant A/New Caledonia/20/99 hemag-
glutinin protein at 3 μg/ml, and incubated 1 hour at 37°
C. 50 μl of plasma/peptide mixture were then added to
50 μl of influenza virus (15xTCID50 of A/Puerto Rico/8/
34 virus in 2% FBS/IMDM) in a flat-bottom 96-well
plate (Corning Incorporated, Corning, New York). The
following controls were in place on every plate: virus
control (50 μl 2% FBS/IMDM plus 50 μl virus); cell con-
trol (100 μl 2% FBS/IMDM); no peptide control (25 μl
diluted plasma plus 25 μl2 %F B S / I M D Mp l u s5 0μl
virus). After these 96-well plates were incubated for 1.5
hours at 37°C, 1 × 10
5 freshly trypsinized MDCK cells
were added to each well. Plates were incubated over-
night for 18-22 hours in a humidified 5% CO2 atmo-
sphere at 37°C.
The following day, media was removed by inversion
and plates were washed once with 200 μlo fP B S .C e l l s
were then fixed by the addition of 100 μlo fc o l d8 0 %
acetone to each well for 10 minutes. After removal of
acetone by inversion, the plates were air-dried for 20
minutes. Plates were then washed 5 times with 300 μl
PBS/0.05% Tween20 and incubated for 1 hour at room
temperature with 100 μl per well of biotinylated influ-
enza A anti-NP antibody (Chemicon International,
Temecula, California) at a dilution of 1/2000 in 5% FBS/
PBS. Plates were washed as before and incubated for 1
hour at room temperature after the addition of 100 μl
per well HRP-conjugated streptavidin (Upstate, Teme-
cula, California) at a dilution of 1/10,000 in 5% FBS/
PBS. Plates were once again washed and incubated at
room temperature with 100 μl per well TMB One Com-
ponent HRP Microwell Substrate. The colorimetric reac-
tion was stopped after 12 minutes by adding 100 μlp e r
well of 450 nm Stop Reagent for TMB Microwell Sub-
strates. The optical density of each well was read at 450
nm using an Emax microplate reader (Molecular
Devices, Sunnyvale, California).
Competitive plaque reduction assay
A previously described and tested protocol was modified
by our group [26]. Briefly, freshly trypsinized MDCK
cells were washed and resuspended in supplemented
IMDM at a concentration of 1.125 × 10
5 cells/ml. Three
millilitres of cell suspension were then seeded into each
well of 6-well tissue-culture treated polystyrene, flat-bot-
tom plates (BD, Franklin Lakes, New Jersey). After 48
hours incubation in a humidified 5% CO2 atmosphere
at 37°C, cells were verified to have reached 90-95%
confluency.
Heat-inactivated A/New Caledonia/20/99-specific
sheep antiserum or human plasma samples were diluted
to a concentration of 1/10 or 1/80, respectively in sup-
plemented IMDM. Individual influenza or HIV peptides
were diluted to 50 μg/ml while recombinant A/New
Caledonia/20/99 hemagglutinin protein was diluted to
10 μg/ml. 50 μl diluted peptide or diluted protein were
added to 50 μl diluted sheep serum or diluted human
plasma and incubated for 1 hour at 37°C. 100 μlo f
influenza virus diluted to 120 plaque-forming units
(PFUs) were then added to the mixture from the pre-
vious step, and once again incubated for 1 hour at 37°C.
Pre-seeded 6-well plates were washed twice with warm
PBS, and 100 μl of mixture were added to the appropri-
ate well. Upon addition to the sample/peptide mixture
the influenza virus was diluted by a factor of 2, therefore
60 PFUs were added to each well. To verify that this
was indeed the amount of virus added, a virus control
(100 μlo fv i r u sd i l u t e dt o6 0P F U s )w a sr u nf o re a c h
sample. A cell control (100 μl PBS alone), and a no pep-
tide control (wherein 50 μl PBS were added to 50 μl
serum/plasma prior to the first incubation) were also
included for each serum/plasma tested. Plates were
incubated for 1 hour at 37°C in a humidified 5% CO2
atmosphere, and were gently rocked back and forth
every 15 minutes throughout the incubation period to
ensure even distribution of virus.
At the end of the incubation, 3 ml of warm overlay
were gently added to each well. Overlay consisted of
equal parts supplemented 2x Minimum Essential Med-
ium (VWR, West Chester, Pennsylvania) (2x MEM con-
taining 2% penicillin/streptomycin, 2% L-Glutamine
(Invitrogen, Carlsbad, California) and 0.25% sodium
bicarbonate (Sigma-Aldrich, St. Louis, Missouri)) and
1.3% agarose (Invitrogen, Carlsbad, California) dissolved
and melted in 100 ml of distilled water. Once MEM/
agarose solution had cooled to 37°C, 0.9 μg/ml of
TPCK-trypsin was added.
After 20 minutes at room temperature, the overlay
had solidified and plates were returned to the incubator
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one part acetic acid) was then added to each well for 30
minutes, and discarded by inversion. The agarose discs
were removed by carefully rinsing plates under a gentle
stream of tap water, and a 0.1% crystal violet solution
was used to stain the wells. After 30 minutes, stain was
rinsed off, plates were allowed to air dry, and plaques
were counted.
Cellular proliferation assay
A protocol previously used in our laboratory was opti-
mized for use with human cells [23,24,27,28]. Briefly,
frozen PBMCs were thawed in a 37°C water bath and
washed twice with 10 ml warm Roswell Park Memorial
Institute (RPMI) medium (Thermo Fisher Scientific,
Waltham, Massachusetts) supplemented with 10% (v/v)
FBS and 1% penicillin/streptomycin. Viable cells were
counted by Trypan blue dye exclusion, and cell suspen-
sions were prepared to a concentration of 2.0 ×
10
6cells/ml. 100 μl of these cell suspensions were added
to 100 μl of each stimulant (individual influenza or HIV
gag peptide at 10 μg/ml or recombinant A/New Caledo-
nia/20/99 hemagglutinin protein at 1 μg/ml). All condi-
tions were tested in triplicate in a round-bottom 96-well
plate (BD, Franklin Lakes, New Jersey). Unstimulated
cells and cells stimulated with PMA/ionomycin were
also included for each donor as negative and positive
controls, respectively.
Plates were incubated at 37°C in a humidified 5% CO2
atmosphere for 48 or 120 hours (PMA/ionomycin-
stimulated cells and peptide/recombinant protein-stimu-
lated cells, respectively). At these time points, 50 μlo f
[methyl-
3H] thymidine (Amersham, Amersham, UK)
diluted 1/100 (to give 0.01 mCi/ml) in supplemented
RPMI were added to each well. Plates were then
returned to the incubator for 16-18 hours.
Cells were then harvested onto glass-fibre filter mats
(PerkinElmer, Waltham, Massachusetts) using an auto-
mated cell harvester (Tomtec, Hamden, Connecticut).
The filter mats were allowed to air dry overnight, and
were then placed in a plastic sample bag and saturated
with Betaplate scint scintillation fluid (PerkinElmer,
Waltham, Massachusetts). Radioactivity was counted on
a Wallac 1450 Microbeta Plus Liquid Scintillation
and Luminescence Counter (PerkinElmer, Waltham,
Massachusetts).
ELISpot assay
IFN-g ELISpot assay was performed as previously
described [23,28]. Briefly, sterile 96-well MultiScreenHTS
filter plates (Millipore, Billerica, Massachusetts) were acti-
vated by the addition of 15 μl of sterile-filtered 35% etha-
nol per well. After 1 minute at room temperature the
plates were washed 5 times with 200 μl PBS, and 100 μl
of Anti human IFN-g mAb (Mabtech, Nacka Strand, Swe-
den) at a concentration of 10 μg/ml in PBS were added
to each well. Coated plates were incubated overnight
at 4°C.
The following day, coating antibody was removed by
washing the plates 5 times with 200 μl per well using
sterile PBS. Plates were blocked for 1 hour at room
temperature with 200 μl per well supplemented RPMI.
After the incubation, blocking medium was removed
by inversion and the cell suspensions containing the
appropriate stimulatory agents were added to each well
as follows.
Frozen PBMCs were thawed and counted using the
same method as above, and cell suspensions were pre-
pared at a concentration of 2.0 × 10
6cells/ml. One hun-
dred microliters (2.0 × 10
5) cells were then added to
each well and stimulated with individual influenza
peptides, HIV gag peptide, or recombinant A/New Cale-
donia/20/99 hemagglutinin protein (diluted to a concen-
tration of 10 μg/ml and 4 μg/ml respectively in
supplemented RPMI). Unstimulated cells were used as a
negative control and PMA/ionomycin stimulated cells
were used as a positive control. All conditions were
tested in duplicate for each donor. The plates were
placed in a plastic container lined with ddH2O-mois-
tened paper towel. This container in turn was placed in
a humidified incubator with 5% CO2 at 37°C and incu-
bated for 48 hours.
Following this incubation, the cells were decanted
and the plates were washed 5 times with 200 μlp e r
well of sterile PBS. Biotinylated anti-human IFN-g
(Mabtech, Nacka Strand, Sweden) was diluted to a con-
centration of 1 μg/ml in PBS/0.5% FBS, and added at
100 μl per well during an incubation of 2 hours at
room temperature. The plates were washed as before
and 100 μl of streptavidin-ALP (Mabtech, Nacka
Strand, Sweden) diluted 1/1000 in PBS/0.5% FCS were
added to each well. Plates were incubated for 1 hour at
r o o mt e m p e r a t u r ea n dw a s h e do n em o r et i m ea s
before. After 100 μl of BCIP/NBT alkaline phosphatase
substrate (Mabtech, Nacka Strand, Sweden) were added
to each well, the plates were incubated in the dark at
room temperature for 20 minutes. Colour development
was stopped by thoroughly washing the plates under
running tap water. The plates were allowed to dry, and
spots were counted using a dissection microscope at a
magnification of 40×.
Statistical analysis
Results are expressed as mean ± SEM. Statistical signifi-
cance of the human donor data was evaluated using the
Mann-Whitney t-test, where a p value equal to or less
than 0.05 was considered significant when compared
with the HIV gag peptide control.
Samayoa et al. Virology Journal 2011, 8:309
http://www.virologyj.com/content/8/1/309
Page 5 of 20Results
Characterization of peptide immunogens
Sixteen synthetic peptides representing the hemaggluti-
nin protein of A/Puerto Rico/8/34 H1N1 strain of influ-
enza were designed. The parent design of these short
immunogens consisted of a T-helper epitope linked by
two glycine spacers to a B-cell epitope (T-B peptide).
Fifteen variations of this basic construct were synthe-
sized; 6 different MAPs, a T-B peptide with an added
N-terminal cysteine residue, a lipidated T-B peptide,
and 7 mutated versions of the T-B peptide (Figure 1).
Branching peptides, or MAPs, were generated by
incorporating lysine residues into the constructs
between the T and B epitopes. Altogether, three differ-
ent types of MAPs were designed: a construct with one
lysine branching point and two chains coming off the
backbone, a similar construct that was lipidated with
palmitic acid at the N-terminus of each of the two
branches, and a larger construct with two lysine branch-
ing points and thus four chains coming off the backbone
(Figure 2). Each of the three types of MAPs was synthe-
sized using the B-cell epitope as a backbone and the T-
helper epitope as branches, and vice versa, for a total of
6 unique designs.
In order to design the mutated peptides, the HA
sequences of all H1N1 genomes from after 1934 were
downloaded from the LANL ISD [21]. When these
sequences were aligned and compared, it was found that
the T-helper epitope had been conserved. Conversely,
the B-cell epitope had three variable sites: WLT[E®G]K
[E®N]G[S®L]YP (where variable sites are shown as
[original A/Puerto Rico/8/34 residue®divergent resi-
due]). All 7 possible mutations of the original epitope
were synthesized and these were reverse-analysed using
the NCBI BLAST program [22] to determine the num-
ber of influenza genomes that each unique epitope
could be found in (Table 1). Comparing the generated
epitopes to the protein sequences available in the NCBI
database revealed that not all epitope mutations were
generated at the same frequency. In fact, three of the
mutated epitopes were very favourable: the T-cell epi-
topes of constructs 138 (mutated at all three variable
positions), 134 (mutated at the second and third variable
positions), and 133 (mutated at the second variable posi-
tion) had over 500, 199, and 86 exact matches, respec-
tively. The unmutated epitope from the A/Puerto Rico/
8/34 strain (construct 122) had 4 exact matches in the
database, including the original strain, while construct
137 (mutated at the first and the second variable posi-
tions) had two exact matches. On the other hand, three
mutated epitopes were not naturally occurring: the T-
cell epitopes of constructs 132, 135 and 136 (mutated at
the third variable position, mutated at the first variable
position, and mutated at both the first and third variable
position, respectively) had no exact matches in the
database.
To determine if the constructs used shared any simi-
larity with human proteins, the peptides were also
screened against the human sequences available in the
NCBI BLAST program. There was no significant simi-
larity found for the peptides, thereby eliminating the
possibility of any autoimmune reactions should our
immunogens be administered to human subjects.
All of the influenza peptides were synthesized in-
house by the solid phase method using an automated
peptide synthesizer, and high-performance liquid chro-
matography (HPLC) was used to analyze the sixteen lyo-
phylates. Analysis of the HPLC peaks showed that the
purity of the peptide preparations ranged between 90-
95% (data not shown).
MAP constructs more effectively bind antibodies in an
ELISA
In order to determine the antibody binding and recogni-
tion patterns of our various influenza peptide construct,
the individual peptides were tested against commercial
influenza strain-specific sheep serum and immune
plasma from vaccinated human donors. ELISA plates
were coated with the sixteen different influenza pep-
tides, an unrelated HIV gag peptide as negative control,
and recombinant hemagglutinin protein from New Cale-
donia influenza strain. Each condition was coated in tri-
plicate; serum and plasma samples were tested in
duplicate under each coating condition, while the third
well was left as a blank and subtracted from the average
OD value.
New Caledonia strain-specific sheep serum (which is
an H1N1 subtype, as the A/Puerto Rico/8/34 strain the
peptides are based on) exhibited preferential binding of
four peptides: 124, 125, 127 and 131, which are lipidated
2-branched MAP T-B peptide; 4-branched MAP T-B
peptide; 4-branched MAP B-T peptide; and lipidated T-
B peptide, respectively (Figure 3).
The peptides were screened using immune human
samples, and peptide 124 (lipidated 2-branched MAP T-
B peptide) showed the most reactivity in terms of anti-
body binding activity (Figures 4 and 5). Three donors
bound 124 (lipidated 2-branched MAP T-B peptide) at
exceptionally high rates: the plasma of donors 1147,
1155 and 1158 bound the peptide very strongly (at an
O Dv a l u ea b o v e2 . 0 0 ,w h i c hi so np a rw i t ht h eO D
values of the positive control, the recombinant hemag-
glutinin protein). An additional two donors, 1146 and
1148, were able to bind peptide 124 at strong rates (OD
values between 1.00 and 1.99). Of the remaining donors,
all except for four donors bound peptide 124 at a higher
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Page 6 of 20ID  Description  MW  Sequence 
122  T-B peptide  2733  SFERFEIFPKE-GG-WLTEKEGSYP 
123  T-B peptide, 2-
branched MAP  4332 
SFERFEIFPKE 
                           ›K-WLTEKEGSYP 
SFERFEIFPKE 
124 
T-B peptide, 
lipidated 2-
branched MAP 
4809 
CH3(CH2)14COOH-SFERFEIFPKE 
                                                          ›KWLTEKEGSYP 
CH3(CH2)14COOH-SFERFEIFPKE 
125  T-B peptide, 4-
branched MAP  7410 
SFERFEIFPKE 
                          ›K 
SFERFEIFPKE 
                          ›K-WLTEKEGSYP 
SFERFEIFPKE 
                          ›K 
SFERFEIFPKE 
126 
B-T peptide, 2-
branched MAP  4113 
WLTEKEGSYP 
                            ›K-SFERFEIFPKE 
WLTEKEGSYP 
127  B-T peptide, 4-
branched MAP  6752 
WLTEKEGSYP 
                            ›K 
WLTEKEGSYP 
                            ›K-SFERFEIFPKE 
WLTEKEGSYP 
                            ›K 
WLTEKEGSYP 
128 
B-T peptide, 
lipidated 2-
branched MAP 
4590 
CH3(CH2)14COOH- WLTEKEGSYP 
                                                             ›K- SFERFEIFPKE 
CH3(CH2)14COOH- WLTEKEGSYP 
129  T-B peptide, N-
terminal cysteine  2837  SFERFEIFPKE-GG-WLTEKEGSYP-Cys 
131 
T-B peptide, 
lipidated  3338  CH3(CH2)14COOH- SFERFEIFPKE-GG-WLTEKEGSYP 
132  Mutated T-B 
peptide 1  2760  SFERFEIFPKE-GG-WLTEKEGLYP 
133  Mutated T-B 
peptide 2  2718  SFERFEIFPKE-GG-WLTEKNGSYP 
134  Mutated T-B 
peptide 3  2745  SFERFEIFPKE-GG-WLTEKNGLYP 
135  Mutated T-B 
peptide 4  2661  SFERFEIFPKE-GG-WLTGKEGSYP 
136  Mutated T-B 
peptide 5  2688  SFERFEIFPKE-GG-WLTGKEGLYP 
137  Mutated T-B 
peptide 6  2646  SFERFEIFPKE-GG-WLTGKNGSYP 
138  Mutated T-B 
peptide 7  2672  SFERFEIFPKE-GG-WLTGKNGLYP 
Figure 1 Sixteen synthetic peptides consisting of a T-helper epitope (SFERFEIFPKE) linked to an immunodominant B-cell epitope
(WLTEKEGSYP) based on the hemagglutinin of influenza virus A/Puerto Rico/8/34 were synthesized. Peptide 122 was a simple,
unmodified T-B diepitope construct. Peptides 123-128 are multiple antigen peptides (MAPs, as depicted schematically in Figure 2), where 〉K
designates a lysine branching point; peptides 124, 128 and 131 are lipidated with palmitic acid, as indicated by CH3(CH2)14COOH; peptides 132-
138 are mutated versions of the original A/Puerto Rico/8/34 T-helper and B-cell epitopes, with each mutation shown in bold type (as
summarized in Figure 1).
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Page 7 of 20rate than all other peptides. Of these, donor 1149 bound
peptide 125 (4-branched MAP T-B peptide) at the high-
est rate, while donors 1150, 1157 and 1159 showed the
highest OD value with peptide 131 (lipidated T-B pep-
tide) (Figure 4a). Interestingly, donor 1145 bound both
peptides 124 and 131 at the highest rate. Examining
mean antibody binding levels, peptide 124 and peptide
131 were clearly preferentially bound even when
averaged across all 16 donors (Figure 5). Overall, pep-
tides 124 and 131 (lipidated 2-branched MAP T-B pep-
tide and lipidated T-B peptide, respectively) showed the
highest levels of antibody binding.
Peptides show some ability to bind neutralizing
antibodies
To determine if the synthetic influenza peptides were
able to bind neutralizing antibodies, we developed two
modified functional assays - a competitive microneutra-
lization assay and a competitive plaque reduction assay.
Both assays assessed the peptides’ ability to inhibit virus
neutralization by binding the neutralizing antibodies
found in immune samples.
In the competitive microneutralization assay, indivi-
dual peptides were incubated with human plasma sam-
ples, and after one hour of incubation influenza virus
was added to the samples. Following an additional incu-
bation time of 1.5 hours, this mix was added to freshly
trypsinized MDCK cells, In theory, any virus that had
not been neutralized by the immune samples would be
free to infect the cells, as evidenced by the detection of
newly-formed virus. As such, cells were incubated over-
night, and then fixed and lysed. Virus growth was mea-
sured by using an antibody directed at the influenza
virus nucleoprotein (NP). Note that for each sample a
peptide-free control was included, and this represented
the baseline level of virus neutralization, which was
Figure 2 Schematic depiction of multiple antigen peptides (MAPs). Specifically, T-helper and B-cell represent the T-helper epitope
SFERFEIFPKE and B-cell epitope WLTEKEGSYP, respectively, both based on the hemagglutinin of influenza virus A/Puerto Rico/8/34. CH3(CH2)
14COOH depicts the addition of a palmitic acid lipid moiety, while K represents a lysine residue used as a branching point.
Table 1 Three variable positions were found in the T-
helper epitope of post-1934 H1N1 genomes (4th, 6th and
8th residue)
ID T-helper epitope Relevance
122 WLTEKEGSYP 4 exact matches, including “original”
A/Puerto Rico/8/34 epitope
132 WLTEKEGLYP No exact matches
133 WLTEKNGSYP 86 exact matches
134 WLTEKNGLYP 199 exact matches
135 WLTGKEGSYP No exact matches
136 WLTGKEGLYP No exact matches
137 WLTGKNGSYP 2 exact matches
138 WLTGKNGLYP > 500 exact matches, including
A/New Caledonia/20/99
All possible mutations were designed and synthesized, and these mutations
are bolded for emphasis. The relevance of the constructs was evaluated by
using the NCBI protein BLAST analysis to determine if the mutations were
naturally occurring, and if so how many influenza genomes encompassed
each combination.
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Page 8 of 20different for each donor. This baseline level was sub-
tracted from each raw value to normalize results across
donors. Lower levels of virus neutralization would result
in higher levels of virus growth (as shown by higher OD
values), and it was thus possible to determine which
peptides were able to bind neutralizing antibodies.
The synthetic influenza peptides were screened by
competitive microneutralization assay using immune
human plasma, and donors 1145. 1147 and 1158 showed
increased reactivity (Figure 6). Examining the average
neutralizing antibody binding levels of all 16 donors to
each peptide, 5 different designs showed increased
immunoreactivity. Peptides 123, 125, 127, 128, and 129
(2-branched MAP T-B peptide, 4-branched MAP T-B
peptide, 4-branched MAP B-T peptide, lipidated 2-
branched MAP B-T peptide, and T-B peptide with an
N-terminal cysteine residue, respectively) were able to
bind neutralizing antibodies at a higher rate, as demon-
strated by a decrease in virus neutralization (Figure 7).
For the competitive plaque reduction assay, peptides
were incubated with influenza strain-specific sheep serum
or human plasma samples for one hour. Influenza virus
was added to the samples, and after an additional hour
of incubation the mixture was added to MDCK cells
pre-seeded onto 6-well plates. As in the competitive
microneutralization, any virus that had not been
Figure 3 Ability of sheep serum positive for antibodies against
A/New Caledonia/20/99 to bind 16 different influenza T-B and
B-T peptides, HIV gag peptide (HIV) and recombinant A/New
Caledonia/20/99 hemagglutinin protein (rHA NC) as measured
by ELISA. Absorbance values (OD 450 nm) are given as a mean of
duplicates at a 1/100 dilution of sera ± SEM with the subtraction of
non-specific binding levels (absorbance value of serum alone
control wells). ELISA was run on three separate days and data
shown is representative of all results.
Figure 4 Summary of ELISA results using plasma from human donors; average OD values of the sixteen donors against the sixteen
synthetic influenza peptides and the included controls. The peptide that resulted in the highest OD value is bolded for each donor, and
higher OD values are highlighted (light grey if between 0.250 and 0.99, dark grey if between 1.00 and 1.99 and darkest grey if above 2.00).
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Page 9 of 20neutralized would infect the cells. Infected cells would be
lysed, and therefore virus growth could be quantified by
counting how many plaques were formed. Cells were
thus incubated for 3 days, after which plates were fixed
and stained to determine plaque formation under each
condition. As before, a no peptide control was included
for each sample to determine the baseline level of virus
neutralization for each donor and this value was sub-
tracted from each plaque count. Like in the competitive
microneutralization assay, higher plaque counts indicated
stronger influences of specific peptides on virus neutrali-
zation and in turn a more effective binding of neutraliz-
ing antibodies.
All constructs (although peptide 136, which is
mutated T-B peptide 5, only to a low extent) were able
to inhibit virus neutralization by commercial A/New
Caledonia/20/99-strain specific sera (Figure 8). In parti-
cular, peptides 123 and 125 (2-branched MAP T-B pep-
tide and 4-branched MAP T-B peptide, respectively)
showed slightly higher binding of neutralizing antibodies
as compared to other constructs.
The assay was conducted with immune human
plasma, and donors 1145, 1147 and 1154 were asso-
ciated with higher general inhibition of virus neutraliza-
tion upon addition of peptides. It should be noted that
the first two of these donors also showed stronger
responses in the competitive microneutralization assay.
On the other hand, addition of influenza peptides to the
plasma of donors 1149, 1151, 1160 and 1161 resulted in
very weak changes in levels of virus neutralization (Fig-
ure 9). Comparing differences in immunoreactivity
between peptides, preferential binding was not limited
to one or two designs; peptides 126, 133, 135, and 138
(2-branched MAP B-T peptide, mutated T-B peptide 2,
mutated T-B peptide 4, and mutated T-B peptide 6,
respectively) all showed increased activity when neutra-
lizing antibody binding was averaged across all donors
(Figure 10).
Figure 5 Global comparison of antibody binding levels of human plasma from 16 different donors against 16 different influenza T-B
and B-T peptides, HIV gag peptide (HIV) and recombinant A/New Caledonia/20/99 hemagglutinin protein (rHA NC) as measured by
ELISA. Absorbance values (OD 450 nm) are given as a mean of duplicates at a 1/100 dilution of plasma with the subtraction of non-specific
binding levels (absorbance value of plasma alone control wells) ± SEM. Individual absorbance values (as presented in Figure 4) are shown by
black circles, while mean OD values (average of all donors) are represented by a bar. The assay was run on three separate days and data shown
is representative of all results. All peptides except 128, 129, 132, 135, and 136 had a p-value lower than 0.05 in a Mann Whitney test.
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were not as straightforward as those of the ELISA
screening. However, overall peptides 123 and 125 (2-
branched MAP T-B peptide and 4-branched MAP T-B
peptide, respectively) showed higher ability to bind neu-
tralizing antibodies.
MAP constructs are able to induce cellular immune
responses
The degree to which our synthetic influenza peptides
activate cellular immune responses was determined with
both cellular proliferation and IFN-g ELISpot assays.
First, human PBMCs isolated from donor samples
were stimulated with individual influenza peptides, an
H I Vg a gp e p t i d e( a san e g a t i v ec o n t r o l ) ,r e c o m b i n a n t
New Caledonia-strain hemagglutinin protein (rHA), and
PMA/ionomycin (as a positive control). Levels of cell
division in response to the different stimulants were
assessed by thymidine incorporation; dividing cells
become radiolabelled and could thus be quantified with
the use of scintillation fluid and a luminescence counter.
The stimulation index (SI) was then calculated by divid-
ing the average number of cells in each stimulated con-
dition by the average number of cells in unstimulated
control wells.
Among the sixteen human samples tested, several
donors had intermediate SIs across all peptides that
were assessed; PBMCs from donors 1145, 1156 and
1161 were not stimulated above an index of 5 by most
of the peptides. However, these values were still signifi-
cantly higher than those associated with the HIV gag
peptide-stimulated PBMCs. On the other hand, donors
1148, 1151, 1159 and 1160 showed a five-fold or greater
increase in proliferation in response to most peptides.
Donor 1159 in particular was a very high responder,
with most peptides inducing SI values above 10 (Figure
11).
In terms of peptide-specific differences, there was not
a clear bias to a particular peptide. As summarized in
Figure 11, lipidated MAP construct 124 (lipidated 2-
branched MAP T-B peptide) was able to induce greater
than 10-fold increases in levels of proliferation in four
donors (donor 1147, 1148, 1154 and 1160 with SI values
of 12.835, 11.375, 10.280 and 18.650, respectively), and
increases between 5-fold and 9.999-fold in another five
donors (donor 1149, 1150, 1151, 1159, and 1159 with SI
values of 6.625, 9.150, 6.590, 6.990, and 5.695, respec-
tively). Although peptides 126 and 131 (2-branched
MAP B-T peptide and lipidated T-B peptide, respec-
tively) stimulated somewhat higher levels of cellular
Figure 6 Average OD values of the sixteen donors against the sixteen synthetic influenza peptides and the included controls as
measured by competitive microneutralization assay. Note that values reflect total background subtraction; adjusted for cells alone control
and peptide-free control wells, except the virus alone control which is shown with only cells alone control wells subtracted. The peptide that
resulted in the largest change in absorbance value as compared to the peptide-free control is bolded for each donor, and higher differences are
highlighted (light grey if between 0.200 and 0.349 and dark grey if above 0.350).
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Page 11 of 20proliferation (mean SI values across all donors), these
were only slight increases compared to the other pep-
tides (Figure 12).
Furthermore, the frequency of IFN-g secretion in the
human PBMCs in response to peptide stimulation was
evaluated. As in the proliferation assay, responses to the
sixteen individual influenza peptides, an HIV gag pep-
tide (as a negative control), recombinant New Caledo-
nia-strain hemagglutinin protein (rHA), and PMA/
ionomycin (as a positive control) were evaluated. Use of
ah u m a nI F N - g ELISpot assay allowed quantification of
cell-mediated immune responses. Results are presented
as average spot forming cell counts (SFC), where
average values had been normalized to account for one
million cells and spontaneous IFN-g production (back-
ground levels in unstimulated control cells had been
subtracted).
Like in the lymphocyte proliferation assay, donors
1145 and 1161 were low responders, with most peptides
resulting in SFC counts of less than 20 cells per million
(although donor 1156 who had low cellular proliferative
responses showed moderate cytokine production). In
applying the above criteria that SFC counts of less than
20 cells per million designate low general responders,
PBMCs from donors 1144, 1146, 1148, 1149, 1150 and
1155 can also be classified as such, since these donors
only produced low levels of IFN-g in response to most
peptides (Figure 13). In stark contrast, donors 1151,
1154, 1156, 1157, 1159 and 1160 were high general
responders; stimulation with most peptides resulted in
SFC counts higher than 20. It should be noted that
donors 1151, 1159 and 1160 also had high general sti-
mulation indexes in the proliferation assay. Peptide 124
(lipidated 2-branched MAP T-B peptide) was able to
Figure 7 Global comparison of neutralizing antibody binding levels of human plasma from 16 different donors against 16 different
influenza T-B and B-T peptides, HIV gag peptide (HIV) and recombinant A/New Caledonia/20/99 protein (rHA NC), as measured by
the inhibition of neutralization of A/Puerto Rico/8/34 influenza virus in a competitive microneutralization assay. Absorbance values are
given as mean of duplicates at a 1/80 dilution of plasma ± SEM. Total background (absorbance of cells alone control and peptide-free control
wells) was subtracted from each raw absorbance value. Individual OD values (as presented in Figure 6) are shown by black circles, while mean
OD values across all donors (average of all donors) are represented by a bar. All peptides except 131 and 138 had a p-value lower than 0.05 in a
Mann Whitney test.
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Page 12 of 20induce very high levels of IFN-g production (more than
100 SFC per million cells) among six donors: donors
1148, 1150, 1151, 1154, 1156 and 1159 had counts of
195, 122.5, 120, 182.5, 127.5 and 132.5 SFC per million
cells, respectively. It was interesting that peptide 124 eli-
cited high responses even in donors 1148 and 1150,
who in general were low responders. Furthermore, in all
but two donors stimulation with peptide 124 resulted in
IFN-g production higher than with any other peptide.
Only donors 1144 and 1147 did not have the highest
peptide-specific response associated with peptide 124.
Rather, these two donors showed the best response to
peptide 134 (mutated T-B peptide 3) and 131 (lipidated
T-B peptide), respectively. Examining peptide-specific
cell-mediated responses, it is clear that peptide 124 is
the best immunogen as it elicited the highest SFC count
when averaged across all the donors (Figure 14). Overall,
peptide 124 (lipidated 2-branched MAP T-B peptide)
proved to be the best immunogen in both the prolifera-
tion and ELISpot assays.
Discussion
In the field of vaccine development, novel alternatives to
traditional immunization approaches are presently being
explored; in the case of influenza virus currently avail-
able vaccines have several inherent drawbacks, as
Figure 9 Average plaque count (after background subtraction, except the virus alone control which is shown directly as counted) of
the sixteen donors against the sixteen synthetic influenza peptides and the included controls. The peptide that resulted in the largest
change in plaque count as compared to the peptide-free control is bolded for each donor, and higher differences are highlighted (light grey if
between 6 and 15 and dark grey if above 16).
Figure 8 Ability of 16 different T-B and B-T influenza peptides,
HIV gag peptide (HIV) and recombinant A/New Caledonia/20/
99 hemagglutinin protein (rHA NC) to bind neutralizing
antibodies in sheep serum positive against A/New Caledonia/
20/99 strain, and thereby inhibit neutralization of A/New
Caledonia/20/99 influenza virus. Number of viral plaques given as
mean of duplicates at a 1/80 dilution of plasma ± SEM. Background
(number of plaques in peptide-free serum wells) was subtracted
from each plaque count.
Samayoa et al. Virology Journal 2011, 8:309
http://www.virologyj.com/content/8/1/309
Page 13 of 20outlined above. Utilizing short synthetic peptides pre-
sents an exciting possibility to replace whole protein or
inactivated virus vaccines. Such constructs are attractive
options, as synthetic vaccine components can be mass-
produced and purified with relative ease, and are fully
customizable [29,30]. However, without the addition of
powerful adjuvants, synthetic epitope-based vaccines are
not highly immunogenic [8,31]. This presents a concern,
as only alum and monophosphoryl lipid A (MPL) have
been tested for human use, and are still under evalua-
tion [5]. We therefore thought it worthwhile to examine
whether the immunogenicity of these potential vaccine
alternatives could be improved.
In the present study, we have investigated the immu-
nogenic potential of totally synthetic influenza peptide
constructs, consisting of a T-helper epitope and a B-cell
epitope of the HA of the A/Puerto Rico/8/34 H1N1
influenza virus strain. It has previously been shown that
this linked T-B peptide construct successfully elicits
both humoral and cellular immune responses when
administered to mice. Although the responses induced
by the linked peptide were only moderate, no significant
responses were detected in mice immunized with equi-
molar amounts of non-linked T and B peptides, suggest-
ing that such a conjugated epitope design is a fair
starting design to develop synthetic peptides of
improved immunogenicity [7]. In an effort to improve
the effectiveness of this simple T-B peptide, we used
various bioinformatic tools (including sequence data-
bases, software to align and compare sequences, and
BLAST analysis) [31] to design and analyze a set of
influenza peptides based on the linked epitope back-
bone. In the studies described herein, several factors
that could improve the efficacy of short synthetic
peptide immunogens were investigated. Namely, we
evaluated lipidation, construction of MAPs, inclusion of
a cysteine residue and various mutations for differences
in immunoreactivity in both humoral and cellular assays.
Figure 10 Global comparison of neutralizing antibody binding levels of human plasma from 16 different donors against 16 different
influenza T-B and B-T peptides, HIV gag peptide (HIV) and recombinant A/New Caledonia/20/99 protein (rHA NC), as measured by
the inhibition of neutralization of A/New Caledonia/20/99 influenza virus. Number of viral plaques are given as mean of duplicates at a 1/
80 dilution of plasma ± SEM. Background (number of plaques in peptide-free serum wells) was subtracted from each plaque count. Individual
plaque counts (as presented in Figure 9) are shown by black circles, while mean plaque counts across all donors (average of all donors) are
represented by a bar. All peptides had a p-value lower than 0.05 in a Mann Whitney test.
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Page 14 of 20Figure 12 Global comparison of ability of 16 different influenza T-B and B-T peptides, HIV gag peptide (HIV) and recombinant A/New
Caledonia/20/99 hemagglutinin protein (rHA NC) to induce proliferation of human PBMCs, as tracked by [
3H] thymidine incorporation.
Stimulants were tested in triplicate and the most outlying value was discarded for each count. Stimulation Index is given as the ratio between the
number of cells dividing in response to antigen-stimulation and unstimulated cells ± SEM. Individual SI values (as presented in Figure 8a) are shown by
black circles, while mean SI values across all donors is represented by a bar. All peptides had a p-value lower than 0.0001 in a Mann Whitney test.
Figure 11 Average Stimulation Index (ratio of cellular proliferation between stimulated and unstimulated cells) of the sixteen human
donors against the sixteen synthetic influenza peptides and the included controls as determined by proliferation assay. The peptide
that resulted in the highest SI value is bolded for each donor, and higher SI values are highlighted (light grey if between 5.000 and 9.999 and
dark grey if above 10.000).
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Page 15 of 20In line with previous findings that T epitopes are less
variable than B-cell epitopes [32], the sequence used for
our T-helper epitope was found to be conserved in all
H1N1 strains recorded since 1934. Such non-variable
regions are postulated to evade mutations during repli-
cation because they have vital viral functions [33], and
therefore inclusion of conserved epitopes in a synthetic
vaccine may result in broad-spectrum protection against
multiple strains and potentially even future variants
[32]. Indeed, various studies, especially those focusing
on the hypervariable HIV-1 virus, have suggested an
advantage in using conserved sequences when designing
prophylactic agents [33].
On the other hand, upon aligning post-1934 H1N1
genomes against the B-cell epitope, this region was
found to be variable at three positions. All possible
mutants were synthesized and evaluated, but the epitope
from the A/Puerto Rico/8/34 strain was chosen as the
“parent epitope” used for the MAP and/or lipidated con-
structs, as this sequence has been previously character-
ized as being immunodominant [34,35].
T h eN C B IB L A S Ts o f t w a r ee m p l o y e di nt h ea b o v e
analysis was also used to compare the epitopes con-
tained in our constructs against the proteins encoded by
the human genome. This is an important step when
designing peptides, as similar sequences could result in
autoimmune reactions upon vaccination of human
patients [5,36]. Upon analysing the sixteen influenza
peptides and the individual epitope components no
similarity whatsoever to the human genome was found,
suggesting that our peptide immunogens would not
induce adverse self-immune reactions.
In order to assess the likely efficacy of the different
B-cell epitope designs in eliciting humoral responses, we
screened the various influenza peptides by ELISA that
measured antibody binding using sera from immunized
sheep and humans. When the peptides were tested
against sera from animals immune to A/New Caledonia/
20/99 H1N1 strain, peptides 124 (lipidated 2-branched
MAP T-B peptide), 125 (4-branched MAP T-B peptide),
127 (4-branched MAP B-T peptide) and 131 (lipidated
T-B peptide) bound the antibodies at high rates. Con-
structs 124, 127, and 131 incorporate two lipid chains,
four T-helper epitopes, or one lipid chain respectively,
suggesting that increased molecular complexity enhances
binding possibly by orienting the B-cell epitope in a more
natural configuration. It was not surprising that peptide
127 was among the most immunoreactive in the ELISA,
Figure 13 Average spot-forming cell counts (as determined by ELISpot assay specific for human IFN-g, per million cells with baseline
IFN-g production in unstimulated cells subtracted) of the sixteen donors against the sixteen different synthetic influenza peptides and
the included controls. The peptide that resulted in the highest SFC value is bolded for each donor, and higher SFC values are highlighted
(light grey if between 20 and 99 and dark grey if above 100).
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T-helper epitope backbone and therefore there were
more epitopes present to bind available antibodies. How-
ever, this peptide was not associated with the highest
binding, perhaps because the added B-cell epitopes were
obscuring one another. Upon screening the peptides with
samples from immunized human patients, a similar trend
arose; constructs 124 (lipidated 2-branched MAP T-B
peptide), 125 (4-branched MAP T-B peptide), and 131
(lipidated T-B peptide) once again bound the antibodies
at higher rates (at statistically significant levels, with p <
0.0001). As in the assays performed with sheep sera,
peptide 124 was the most reactive. Interestingly, the
constructs with multiple B-cell epitopes did not perform
well in the assays utilizing human plasma.
Neutralizing antibodies, specifically those directed at
the HA protein, have been characterized as being of
major importance in protection against influenza infec-
tion [3,32,37,38]. The ELISAs above measured direct
antibody binding, but not all these antibodies may be
neutralizing; this assay assesses binding of all virus-spe-
cific antibodies while only those that actually inhibit
viral functions might offer protection [38]. We therefore
modified two developed assays [25,26] that quantify
functional binding to incorporate a competitive aspect.
Binding of neutralizing antibodies was characterized
indirectly via inhibition of virus neutralization, whereby
a peptide was deemed an effective immunogen if it
was able to preferentially bind neutralizing antibodies
resulting in decreased virus neutralization by immune
samples.
Pre-incubating immune human samples with any of
the synthetic influenza peptides prior to testing by com-
petitive microneutralization assay resulted in decreased
virus neutralization as compared to the HIV gag peptide
control, indicating that neutralizing antibodies were
indeed being bound. Specifically, constructs 123, 125,
127, 128, and 129 were associated with larger changes
Figure 14 Global comparison of ability of 16 different influenza T-B and B-T peptides, HIV gag peptide (HIV) and recombinant A/New
Caledonia/20/99 (rHA NC) to induce IFN-g production in human PBMCs. Stimulants were tested in duplicate, and adjusted average
numbers of spot-forming cells (SFC) per one million cells are shown ± SEM (baseline level of IFN-g production in unstimulated cells was assessed
in each donor and subtracted from individual counts). Individual SFC values (as presented in Figure 13) are shown by black circles, while mean
SFC values across all donors (average of all donors) are represented by a bar. All peptides except 128, 129, 136, and 137 had a p-value lower
than 0.05 in a Mann Whitney test.
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with a B-cell epitope backbone four T-helper epitope
arms) and 127 (MAP with a T-helper epitope backbone
four B-cell epitope arms) were both associated with
increased binding activity in at least one of the two
types of ELISA screening. Meanwhile, constructs 123
and 128 (branched peptides with a B-cell epitope back-
bone and two T-helper epitope arms or a T-helper epi-
tope backbone with two lipidated B-cell epitope arms,
respectively) are also MAP constructs, in which the B-
cell epitopes were presumably found in an orientation
similar to that in the native HA protein, a factor that
leads to enhanced recognition and binding by neutraliz-
ing antibodies. The other lipidated MAP design (peptide
124), which was the most reactive in the ELISA screen-
ings, was not included in the above group of peptides
that showed high reactivity. However, this construct was
still able to bind neutralizing antibodies, and performed
on par with the unmodified peptide (construct 122).
Construct 129, with an N-terminal cysteine residue at
the T-helper epitope end, was included in this study to
address the concern that oxidation of this residue could
cause peptides to crosslink via disulfide bonding, result-
ing in impaired immunoreactivity. Indeed, a previous
study found that an air-oxidized T-cell epitope from
hen egg-white lysozyme inefficiently stimulated T-cells
[39]. However, this peptide contained two cysteine resi-
dues within the same epitope which presumably caused
intra-peptide bonds (and incorrect folding). The con-
struct in our study, containing a single cysteine residue,
seems to be undergoing inter-peptide disulfide bonds.
Oxidation thus actually enhanced the immunoreactivity
of peptide 129 in functional humoral assays, possibly
because cross-linking resulted in heavier molecules. In
terms of immunoreactivity in cellular assays, construct
129 proved as efficient or a better immunogen than its
non-cysteinated equivalent peptide 122 (refer to Figure
12 and 14). Also of note, all mutant peptides (132 - 138)
were associated with decreased virus neutralization rela-
tive to the original construct (122). The non-mutated
B-cell epitope has previously been characterized as
being immunodominant, and therefore these results sug-
gest that the mutations that were incorporated were suf-
ficient to decrease immunoreactivity.
It should be noted that it was necessary to use two
different virus strains for the competitive microneutrali-
zation assay and the competitive plaque reduction assay.
The latter assay was incubated for 3 days, during which
the A/New Caledonia/20/99 strain used grew to high
enough viral titers to detect infectivity. On the other
hand, the competitive microneutralization assay had pre-
viously been optimized for overnight incubation. The
influenza virus strain used in the competitive plaque
reduction assay was tested, but did not grow to
detectable levels in this shorter amount of time (data
not shown). Thus another influenza H1N1 virus strain
(A/Puerto Rico/8/34) was used. However, the results of
the competitive plaque reduction assay were still some-
what in agreement with those of the competitive micro-
neutralization assay. When screening the constructs for
neutralizing antibody binding activity by competitive
plaque reduction assay using sera from sheep immune
to the H1N1 strain A/New Caledonia/20/99, again all
constructs were able to inhibit virus neutralization rela-
tive to the negative control (HIV gag peptide). Further-
more, peptides 123 and 125 gave better results, as
determined by a higher plaque count. These two pep-
tides were also among the high binders in the competi-
tive microneutralization assay. When the various
peptides were screened using immune human plasma
samples, the results were quite a bit different. Once
more, all influenza peptides were able to bind neutraliz-
ing antibodies to some degree when compared to the
HIV gag peptide control. Peptides 123 and 125 (MAP
constructs with two or four T-helper epitope arms on a
B-cell epitope trunk, respectively) were, as in the pre-
vious functional binding assays, more efficient immuno-
gens than peptide 122, the “original” backbone
construct. However, these two peptides were not asso-
ciated with the highest reactivity. Rather, peptides 126,
133, 135, and 138 showed the largest change in plaque
count (statistically significant, with p < 0.0001, p =
0.0004, p = 0.0002, and p = 0.0027, respectively). Peptide
126 is a MAP construct with two B-cell epitopes, and
should in theory be able to bind more neutralizing anti-
bodies simply because there are more available binding
sites. However, this peptide had not been among the
better immunogens in the other binding assays, whether
functional or not. It was quite interesting that three
mutated B-cell epitopes were among the higher binding
peptides. Although the B-cell sequences of constructs
133 and 138 had been found to have 86 and over 500
matches in the NCBI database, respectively, peptide 135
did not have any exact matches. In other words, a
sequence that does not actually occur under natural cir-
cumstances was able to effectively bind neutralizing
antibodies. It should be stressed that these results are
those of the average plaque counts of all 16 human
donors. Individual responses were fairly varied, both in
terms of which peptides had the largest effect on plaque
count and the degree of this effect.
In order to study cellular responses as stimulated by
our constructs, the ability of the various synthetic influ-
enza peptides to induce human PBMCs to mount a
proliferative response and to produce IFN-g was investi-
gated. Examining peptide-induced proliferation across all
16 donors, all synthetic influenza T-B dipeptide con-
structs were effective stimulants (comparable to the
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tion with peptide 126 or 131 (two B-cell epitope arms on
a T-helper epitope trunk or lipidated T-B peptide, respec-
tively) led to slightly higher average stimulation (with p <
0.0001), however overall cell-mediated immune responses
were not substantially high. These results were not sur-
prising as we were working with cells from a varied
human donor group. The T-helper epitope included in
this study is known to be recognized by murine MHC
class II molecule IE
d [40]. Moreover, cell-mediated
immune responses depend on proper antigen presenta-
tion by HLA molecules which are highly polymorphic
[36,41]. However, it is reasonable to expect that the
T-helper epitope investigated herein can elicit T-cell epi-
tope responses in humans and in the context of several
HLA alleles (perhaps more effectively so in association
with specific HLA types than with others, as evidenced
by the low general stimulation). It is thus reasonable to
examine donor-specific responses, and it becomes impor-
tant to note that the PBMCs from > 50% of patients
proliferated at levels higher than 5-fold relative to unsti-
mulated control cells in response to peptide 124 (lipi-
dated 2-branched MAP T-B peptide).We expected this
construct to induce a robust proliferative response, as it
has two T-helper epitopes that are flanked by lipid moi-
eties. Thus it has multiple and structurally stable epitopes
available for presentation, and may therefore be captured
by more APCs thereby initiating a stronger cellular
immune response.
Examining the IFN-g secretion showed that peptide
124 is a suitable immunogen. This construct, even when
looking at average IFN-g production in all 16 donors,
induces far higher levels of this cytokine than any of the
other constructs (p < 0.0001).
In summary, although peptide 125 (MAP with four
T-helper epitopes on a B-cell backbone) was best across
all antibody binding assays, peptide 124 was best overall
- this construct performed well in binding assays and
resulted in the highest overall cellular immune
responses. Thus it appears that the design of construct
124 (lipidated MAP with two T-helper epitopes on a B-
cell backbone) is optimal as evaluated herein. The
branched and lipidated nature of this molecule may be
positioning the B-cell epitope in an optimal conforma-
tion, while there are several T-helper epitopes that are
lipid-stabilized, leading to proper presentation to multi-
ple T-cells. It would be worthwhile to evaluate peptides
of interest in vivo, and also possibly to apply similar
modifications to other known epitopes of other hyper-
variable viruses such as HIV and HCV.
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